Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02206802
Other study ID # AB-IVD-MINOXIDIL-004
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 2014
Est. completion date October 2018

Study information

Verified date October 2018
Source Applied Biology, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary purpose of this study is to evaluate the clinical validity of the minoxidil response in-vitro diagnostic kit.


Description:

Topical minoxidil is the only US FDA approved drug used for the treatment of AGA in females. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i.e., 30-40% re-grow hair. To observe significant improvement in hair growth, minoxidil is typically used once daily for a period of at least 24 weeks. Due to the significant time commitment and low response rate, a diagnostic test to identify non-responders prior to initiating therapy would be advantageous.

Minoxidil is converted in the scalp to its active form, minoxidil sulfate, by the sulfotransferase enzyme SULT1A1. The enzyme expression is variable among individuals. We have demonstrated in two prior feasibility studies that the SULT1A1 enzyme activity in plucked hair follicles correlates with minoxidil response in the treatment of AGA and thus can server as a predictive biomarker.

Consequently, we developed a minoxidil response in-vitro diagnostic kit intended to identify non-responders prior to initiating therapy with 5% topical minoxidil foam.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date October 2018
Est. primary completion date October 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Females in overall good health

- Age: 18 or older

- Female pattern hair loss

- Willing to have a mini dot tattoo placed in the target area of the scalp

- Willing to maintain the same hair style, color, shampoo and hair products use, and approximate hair length throughout the study

- Able to give informed consent

- Able to comply with the study requirements for 24 consecutive weeks

- Willing to use an adequate method of birth control (if applicable)

- Negative urine pregnancy test

Exclusion Criteria:

- Previous adverse event from topical minoxidil treatment

- History of hypotension

- Uncontrolled hypertension

- Pregnant, nursing, or planning a pregnancy during the study

- Prior hair transplant

- Uses wigs or hair weaves

- Have used minoxidil (topical or oral) anytime during the past 6 months

- Chronic scalp disorders that require medications

- Uses medication known to cause hair thinning such as Coumadin and anti-depressants/anti-psychotics

- Folliculitis

- Scalp psoriasis

- Seborrheic dermatitis

- Inflammatory scalp conditions such as lichen planopilaris

- Enrolled in any other medical study or has been enrolled in any medical study in the past 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
5% minoxidil topical foam
5% minoxidil topical foam

Locations

Country Name City State
Australia Sinclair Dermatology East Melbourne
India LTM Medical College & Hospital Mumbai
Italy Istituto Medico Tricologico/Studi Life Cronos Florence
United States Tennessee Clinical Research Center Nashville Tennessee
United States Physicians Hair Institute Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Applied Biology, Inc.

Countries where clinical trial is conducted

United States,  Australia,  India,  Italy, 

References & Publications (4)

Buhl AE, Waldon DJ, Baker CA, Johnson GA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990 Nov;95(5):553-7. — View Citation

Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2014 May-Jun;27(3):171-3. doi: 10.1111/dth.12111. Epub 2013 Nov 27. — View Citation

Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004 Feb;150(2):186-94. Review. — View Citation

Roberts J, Desai N, McCoy J, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatol Ther. 2014 Jul-Aug;27(4):252-4. doi: 10.1111/dth.12130. Epub 2014 Apr 28. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the change in Target Area Hair Count Number of hairs measured in the target area by macrophotography. baseline to week 24
Primary Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the subjects ratings baseline to week 24
Secondary Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the change in Target Area Hair Count Number of hairs measured in the target area by macrophotography. baseline to week 12
Secondary Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the treatment efficacy evaluated by expert panel review of global photographs assessing hair regrowth baseline to week 24
Secondary Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the mean change in non-vellus hair diameter in the target region baseline to week 24
Secondary Mean change in minoxidil sulfotransferase activity in plucked hairs as measured by the minoxidil response in-vitro diagnostic kit baseline to week 24
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04953416 - Fractional Non-ablative Laser for the Treatment of Hair Loss N/A
Completed NCT01929330 - Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers Phase 1
Recruiting NCT05213936 - Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color N/A
Completed NCT02919735 - Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN) Phase 2
Recruiting NCT02591823 - Hair Fall in Patients on Low Dose Methotrexate N/A
Enrolling by invitation NCT01651689 - Hair Counts From Vertical and Horizontal Sections of Scalp Biopsy SPecimens in Thai Population With Alopecia N/A
Completed NCT01189279 - Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia Phase 1
Recruiting NCT01111981 - Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Phase 4
Terminated NCT01385839 - Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata N/A
Active, not recruiting NCT03382184 - Fractional Photothermolysis for Hair Follicle Induction Early Phase 1
Not yet recruiting NCT05544448 - In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases N/A
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A
Completed NCT06409650 - To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia Phase 2
Recruiting NCT00801086 - Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain Phase 2
Completed NCT06095739 - Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002 N/A
Completed NCT05587699 - The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A Phase 1
Completed NCT03351322 - ENERGI-F701 for Female Hair Loss Treatment Phase 2
Terminated NCT02935569 - Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy N/A
Completed NCT01590238 - Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Phase 3
Not yet recruiting NCT01557491 - Hair Regrowth After Bicoronal Incision N/A